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Idiopathic pulmonary fibrosis (IPF) is a severe, rapidly progressive diffuse lung disease. Several pathogenetic mechanisms
have been hypothesized on the basis of the fibrotic lung damage occurring in this disease, and a potential profibrotic role of
activated alveolar macrophages and their mediators in the pathogenesis of IPF was recently documented. This paper focuses on
recent literature on potential biomarkers of IPF derived from activated alveolar macrophages. Biomarker discovery and clinical
application are a recent topic of interest in the field of interstitial lung diseases (ILDs). Cytokines, CC-chemokines, and other
macrophage-produced mediators are the most promising prognostic biomarkers. Many molecules have been proposed in the
literature as potential biomarker of IPF; however, a rigorous validation is needed to confirm their clinical utility.
1. Introduction
Interstitial lung diseases (ILDs) are a heterogeneous group of
rare diseases with different etiopathogenesis and clinical evo-
lution [1]. They include idiopathic pulmonary fibrosis (IPF),
a chronic progressive lung disease of unknown etiology, and
a prognosis of 3–5 years [2]. The difficulty of early diagnosis
of IPF, of differentiating IPF/UIP from various idiopathic
interstitial pneumonias and the impossibility of predicting
patient outcome (as there exist different phenotypes of IPF)
have prompted research into biomarkers [3]. The need for
diagnostic and prognostic biomarkers is a topical subject
for all chest physicians involved in the management of
ILD patients and particularly IPF. Useful biomarkers have
to be readily detectable in biological fluids by noninvasive
and reproducible procedures and must be demonstrated
sufficiently sensitive and specific by appropriate statistical
analysis [4]. Identification of new biomarkers of ILD is
a growing field of research, favoured by the development
of new technologies such as genomics and proteomics
that can reveal genetic mutations, polymorphisms, proteins,
peptides, and other molecules with a potential role as
biological indicators [5, 6]. Modern clinical management of
patients with IPF envisages biomarkers with diagnostic and
prognostic value, though not a single biomarker, has yet
provided sufficient evidence to be implemented in routine
patient management [3].
Several pathogenetic mechanisms have been postulated
on the basis of fibrotic lung damage occurring in patients
with IPF. The inflammatory theory has been partially
replaced by the concept of aberrant wound healing due to
interactions between epithelial cells and fibroblasts, deter-
mining uncontrolled chronic fibroproliferation [7]. More
recently, studies on cytokine and chemokine expression in
serum and BAL have suggested a potential profibrotic role
of activated alveolar macrophages and their mediators in
the pathogenesis of IPF [8, 9]. For example, IL13 and
some CC-chemokines are directly implicated as mediators
of these macrophages [10]. Alveolar macrophages are a
heterogeneous population of cells derived from monocytes,
with multiple immunological functions. They defend the
lungs by phagocytic activity, taking part in aspecific mech-
anisms of defence as well as specific immune responses
via secretory activity [11, 12]. Alveolar macrophages are
the most abundant cell population in bronchoalveolar
lavage (BAL). Activated alveolar macrophages can release
cytokines, growth factors, extracellular matrix proteins, and
tissue inhibitors of metalloproteases, contributing to alveolar
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Table 1: The main features of macrophage-derived biomarkers of idiopathic pulmonary fibrosis.
CCL18 IL8 CCL2 S100A9 MIF
Cellular production
Monocytes/
Macrophages,
Dentritic cells
Macrophages,
Epithelial cells
Monocytes/
Macrophages,
Fibroblasts,
Epithelial cells,
Endothelial cells
Monocytes/
Macrophages,
Neutrophils
Macrophages,
T cells
Biological fluids
Serum, Lung
tissue, BAL
Serum, BAL Serum, BAL BAL, Lung tissue BAL, Lung tissue
Concentrations in
IPF versus controls
Increased Increased Increased Increased Increased
Correlation studies
with clinical
parameters
YES YES YES YES None
Studies on other
ILDs (specificity)
Sarcoidosis, NSIP,
Systemic sclerosis,
Hypersensitivity
pneumonitis, Vasculitis,
Smoking-related ILD
Sarcoidosis,
Systemic
sclerosis, BOOP,
Vasculitis,
Hypersensitivity,
pneumonitis
Sarcoidosis,
Systemic sclerosis
Hypersensitivity,
pneumonitis, BOOP,
AIP, Silicosis
Sarcoidosis,
Systemic sclerosis
Sarcoidosis,
Wegener’s
granulomatosis,
Systemic sclerosis,
Hypersensitivity
pneumonitis
Studies on other
lung diseases
Malignancies,
TB, Asthma
Bronchiolitis,
Cancer,
Asthma COPD,
Cystic fibrosis,
ARDS
Malignancies,
Asthma, TB
Malignancies,
Pneumonia
Lung cancer,
Pneumoniae,
Asthma, ARDS
injury and aberrant lung repair occurring in IPF [13–16].
Study of the macrophage model of activation suggests the
existence of classical and alternative modes of activation.
The classical mode is mediated by type 1 proinflammatory
cytokines, while type 2 cytokines induce the alternative
mode, facilitating release of profibrotic mediators and pro-
moting fibrogenetic processes with aberrant production and
deposition of collagen in the lungs [15, 16]. Studies on BAL
fluid show that alveolar macrophages have a crucial role in
the pathogenesis of ILD in general, for example, in sarcoido-
sis, where they mediate abnormal lymphocyte proliferation
and granuloma formation by inducing antigen presentation
[17, 18]. In IPF, alveolar macrophages play a profibrotic
role through release of fibronectin, insulin growth factor,
PDGF, and other mediators [19, 20]. Alternative activated
macrophages (M2 phenotype) are crucial in the pathogenesis
of IPF enhancing fibrogenesis of fibroblasts by providing
profibrogenic factors [21], favouring cell growth, collagen
formation, and tissue repair [22]. Prasse et al. demonstrated
that alternative activated macrophages trigger a vicious circle
between alveolar macrophages and fibroblasts by releasing
IL10, IL1 receptor antagonist, and CCL18 (also named PARC
or MIP-4), which promote collagen deposition and fibrotic
progression of IPF [9]. Moreover, very recently Pechkovsky
et al. confirmed the crucial role for M2 macrophages in
the pathogenesis of IPF reporting elevated spontaneous
production of the chemokines CCL17, CCL18, and CCL22
and increased expression of CD206 by alveolar macrophages
from patients with lung fibrosis. They also obeserved that
IL-4 was the most powerful inducer of M2-phenotype in
alveolar and monocytes from IPF patients [15].
Analysis of recent literature on biomarkers derived from
activated alveolar macrophages in IPF is the main topic of
this paper.
2. Macrophage-Derived Biomarkers of IPF
In the last few years, molecules of different origin have
been proposed as potential biomarkers of IPF. Fibrocytes,
neutrophils, and alveolar epithelial cells are sources of medi-
ators involved in the pathogenesis of IPF and proposed as
candidate biomarkers, for example, KL6, surfactant proteins
A and D, or circulating fibrocytes [23–26]. Although many
molecules expressed by alveolar macrophages (cytokines
such as IL13 and TGF-beta, CC chemokines, and many
enzymes, receptors, and growth factors, such as PDGF) have
been studied in different biological fluids of IPF patients
in order to evaluate their contribution to pathogenesis,
only a limited number have been investigated for clinical
biomarker potential by seeking correlations between their
concentrations and parameters of clinical prognostic [3, 15,
21, 27–32].
CC Chemokine Ligand 18 (CCL18). has been widely studied
in BAL, serum, and tissue of IPF patients, proving a very
promising biomarker derived from alternatively activated
alveolar macrophages (Th2 cytokines and IL10 induce its
biosynthesis) and highly expressed in the lungs [15, 33–
35] (Table 1). In 2006, a group of German researchers
demonstrated that normal human alveolar macrophages
express CCL18 spontaneously, but its production is much
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higher (more than 100-fold) in IPF patients than controls
[15]. They also demonstrated that contact and exposure of
fibroblasts to native collagen induces spontaneous release of
CCL18 by M2 macrophages, which also upregulate collagen
production by lung fibroblasts [15]. CCL18 has therefore
been recognised as a mediator of positive feedback between
alveolar macrophages and fibroblasts, promoting collagen
deposition in IPF. The effectiveness of CCL18 as a biomarker
of IPF activity was later documented by measuring its con-
centrations in serum, BAL, and BAL cell supernatants from a
group of IPF patients [33]. Concentrations in serum strictly
reflected the time trend of certain functional parameters
(such as TLC) in these patients. An inverse correlation was
also found between spontaneous release of BAL CCL18 and
TLC or DLCO; as well, a direct correlation was demonstrated
between BALCCL18 concentrations and BAL neutrophil and
eosinophil counts [33]. The prognostic value of CCL18 was
recently reported in a prospective study that documented
significantly higher mortality in IPF patients with serum
CCL18 concentrations above 150 ng/ml [35]. High levels of
CCL18 in serum were associated with high risk of disease
progression. CCL18 is therefore an importantM2 biomarker;
its concentrations are elevated not only in serum of IPF
patients but also in other ILDs with active fibrosis, and to a
lesser extent in serum of patients with bronchial asthma and
rheumatoid arthritis [33, 34]. Extension of CCL18 studies
to a larger population will enable definition of its potential
use in clinical practice for the management of IPF patients.
This chemokine could be particularly useful, especially as a
prognostic indicator of patient survival.
Alveolar macrophages can release other CC chemokines
that could be implicated in fibrogenesis, including CC
chemokine ligand 2 (CCL2 or monocyte chemoattractant
protein-1, MCP-1) that together with CCL3 and CCL4,
proved higher in BAL of IPF patients than controls [8, 32, 36–
38]. CCL2 levels in BAL were inversely correlated with DLCO
values and arterial oxygen tension in IPF [32, 36]. Shinoda et
al. suggested that elevated concentrations of CCL2, CCL17,
and CCL22 in BAL fluid may be predictive of poor outcome
in patients with IPF, being associated with poor survival rate
[32]. Concentrations of CCL-2 can also be increased not
only in BAL but also in serum and of IPF patients (Table 1);
indeed, Suga et al. suggested that the clinical evolution
of the disease is correlated with serum CCL2 chemokine
concentrations [37]. The potential application of CCL2 as
a clinical biomarker of IPF seems to be limited by its low
specificity; its serum concentrations are higher in connective
tissue lung diseases than in IPF, and common nonrespiratory
diseases such as atherosclerosis may raise levels, acting as a
confounding factor [38, 39].
IL-8. (also known as neutrophil chemotactic factor) is a
major mediator of inflammatory response. Produced by
alveolar macrophages, epithelial cells, and other cell types,
it functions as a chemoattractant for neutrophilic granu-
locytes, macrophages, endothelial cells, and mast cells and
as a potent angiogenic factor [40]. Concentrations of IL-
8 in serum can be influenced by several factors, including
infectious diseases (Table 1) [41]. More than 10 years ago,
Ziegenhagen et al. reported higher concentrations of this
CXC chemokine in serum and BAL of patients with IPF
than normal controls [42]. They also reported positive
correlations between serum and BAL concentrations of IL-8
and neutrophil percentages in BAL [42]. Serum levels of this
chemokine were inversely correlated with lung function data
(DLCO, VC, TLC) and oxygen pressure measured by blood
gas analysis in this population of IPF patients. The authors
suggested that IL-8 may be a useful clinical marker in the
followup of IPF patients [42]. After this study, other research
confirmed the very high levels of IL8 in serum of IPF patients,
as well as inverse correlations with functional parameters
(mainly FVC) [43, 44]. A Japanese study indicated that
high serum levels of IL-8 can be observed in patients with
active disease, while stable IPF patients had low serum
concentrations of IL-8 [44]. The correlation between IL8
concentrations and mortality rate has never been tested. IL-
8 is a potential biomarker of IPF with limited specificity
that could possibly be included in a cluster of biomarkers to
define their effective prognostic power in a larger group of
patients.
The complex pathogenetic mechanisms and lack of
diagnostic and prognostic biomarkers of IPF have driven
proteomic research in the last few years. Several proteomic
studies have been done, and a proteomic approach has been
used to analyse protein composition of BAL from different
ILD, including IPF, identifying proteins of interest [6, 45–
49]. Calgranulin B and MIF, produced by activated alveolar
macrophages were among those expressed differently in IPF
patients than controls [49–51] (Table 1).
Calgranulin B (S100A9 or MRP14). Is a S100 protein pro-
duced by monocyte-macrophages, neutrophils, and other
cells mainly in response to chronic inflammatory processes
[52]. S100A9 is involved in the regulation of a number
of cell processes such as cell cycle progression and dif-
ferentiation [53]. Recent data suggests that this protein
has a crucial role in inflammation, cancer, and fibrotic
lung remodeling [54]. It interacts with extracellular matrix
proteins, stimulates fibroblast proliferation, and regulates
transendothelial migration of leukocytes and adhesion of
neutrophils to fibrinogen via beta 2 integrin Mac-1 [55,
56]. Its interactions with RAGE receptors (other profibrotic
agents implicated in the regulation of extracellular matrix
degradation in IPF) facilitate neutrophil migration from
endothelium to interstitium, adhesion of neutrophils to
fibronectin, and fibrotic lung remodeling [57]. Calgranulin
B is overexpressed in breast, lung and gastrointestinal cancer,
autoimmune inflammatory diseases, and COPD and cystic
fibrosis [58–60]. In 2002, calgranulin B was identified for
the first time in BAL of IPF and sarcoidosis patients by a
proteomic approach using gel matching and MALDI-TOF
mass fingerprinting [49]. Percentage volumes of calgranulin
B proved significantly higher in BAL of IPF patients than
sarcoidosis patients or patients with pulmonary fibrosis
associated with systemic sclerosis or controls (Figure 1)
[45]. Quantitative analysis (ELISA) confirmed the very high
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Figure 1: Calgranulin B concentrations in BAL of sarcoidosis, idio-
pathic pulmonary fibrosis patients and healthy controls (smokers
and nonsmokers). The box extends from the 25th percentile to the
75th percentile, with a line at the median (the 50th percentile).
Prism plots the whiskers to extend above and below the box to show
the highest and lowest values [61].
concentrations of this protein in BAL of IPF patients,
presumably due to the elevated number and massive acti-
vation of polymorphonuclear cells in this disease (indeed
calgranulin B concentrations in BAL showed a positive
correlation with neutrophil/eosinophil percentages in BAL)
[50]. The suitability of BAL calgranulin B as a disease
biomarker was suggested by an inverse correlation with
FVC and DLCO; the highest concentrations of calgranulin
B in BAL were observed in patients with the lowest FVC
and DLCO values [61]. Elevated BAL concentrations of
calgranulin B in IPF patients and a correlation with BAL
neutrophil counts were recently also confirmed by Korthagen
et al. who additionally reported a moderate increase in
this protein, correlated with radiological stages, in BAL of
sarcoidosis patients [62]. Further study of calgranulin B
as a potential indicator of IPF severity and sarcoidosis is
warranted. The protein expression has to be analysed in
serum of IPF patients and in order to verify its specificity
also in serum and BAL samples of patients with different
interstitial lung diseases.
Another interesting protein identified by a proteomic
approach in BAL of patients with IPF and differently
expressed in patients than controls is macrophage migration
inhibitory factor, MIF. MIF is a pleiotropic proinflammatory
cytokine produced by activated macrophages and potentially
involved in IPF pathogenesis for its numerous functions
including regulation of cell redox status, inhibition of apop-
tosis, induction of matrix metalloproteinases, and regulation
of Th1/Th2 immune responses [51]. Its concentrations in
BAL of IPF patients are very high and directly correlated with
BAL neutrophil percentages. Immunohistochemical analysis
of MIF revealed enhanced expression from actively fibrosing
areas, such as fibroblast foci and lung remodeling zones
[51]. The role of MIF as a disease biomarker needs to be
investigated. Potential correlations with clinical parameters
(including mortality rate) in IPF patients and the expression
of MIF in other interstitial lung diseases have to be furtherly
analysed.
3. Conclusion
The recent literature on IPF indicates great interest in
developing diagnostic and prognostic biomarkers and in
defining the potential role of activated macrophages in the
pathogenesis of IPF. Potential IPF biomarkers derived from
activated alveolar macrophages, currently being studied,
include CCL18, CCL2, IL-8, and calgranulin B.
The discovery and development of biomarkers has to
be conducted in a rigorous manner; studies on potential
biomarkers have to be performed on a large scale, and
appropriate statistical analysis is necessary to validate a
molecule as a real biological indicator [4, 63]. In the last few
years, only a limited number of molecules analysed in ILD
have made the transition from candidate to true biomarker
status because of the difficulties associated with validating
biomarkers. Among those analysed in this paper, CCL18
seems the most promising macrophage-derived biomarker
of IPF, especially because it is clearly correlated with patient
mortality [35]. However, before serum assay of CCL18 can
be used in the clinical management of IPF patients, further
analysis on a larger populations is required.
Macrophage-derived biomarkers of IPF are proteins
overexpressed in serum, BAL samples, or lung tissue of
patients with IPF compared with controls. An alternative
approach to identify potential bioindicators of IPF has been
suggested by Ren et al. who reported evidence of impaired
transcription in IPF macrophages. The authors concluded
that the detection of a decrease in a specific protein produced
by macrophages would be an alternative method to identify
potential bioindicators of this severe interstitial lung disease
[64].
Sophisticated methods applied to different biological
fluids are revealing interesting new groups of molecules
that could provide future biomarkers of IPF, useful for fine
phenotyping of patients and for clinical management of the
disease.
Abbreviations
BAL: Bronchoalveolar lavage
IPF: Idiopathic pulmonary fibrosis
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2-DE: Two-dimensional electrophoresis.
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